Literature DB >> 10383008

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure.

N D Vaziri1, G Deng, K Liang.   

Abstract

BACKGROUND: Chronic renal failure (CRF) is associated with hypertriglyceridaemia and depressed plasma high-density lipoprotein (HDL)-cholesterol and apolipoprotein A-I (Apo A-I) concentrations. Uraemic hypertriglyceridaemia is due, in part, to lipoprotein lipase and hepatic lipase deficiencies, which are causally linked to excess parathormone (PTH). This study was designed to test the hypothesis that depressed plasma concentration and abnormal composition of HDL in CRF may be due to dysregulation of hepatic expression of Apo A-I and/or the newly discovered HDL receptor.
METHODS: Hepatic Apo A-I and HDL receptor mRNA abundance (Northern blot), and HDL receptor protein mass (Western blot) were determined in CRF rats (5/6 nephrectomy), parathyroidectomized CRF rats (CRF-PTx) and sham-operated controls.
RESULTS: The CRF group exhibited normal hepatic HDL receptor mRNA and HDL receptor protein abundance coupled with reduced hepatic Apo A-I mRNA. Hepatic Apo A-I mRNA, HDL receptor mRNA and protein abundance were not affected by PTx.
CONCLUSIONS: CRF results in the down-regulation of hepatic Apo A-I gene expression, which accounts for the known reduction in plasma Apo A-I concentration. However, CRF does not affect HDL receptor mRNA or protein expression in this model. Neither Apo A-I nor HDL receptor expression were modified by PTx in CRF rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383008     DOI: 10.1093/ndt/14.6.1462

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  32 in total

1.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

Review 2.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

Review 3.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

4.  Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation.

Authors:  Waqas Aftab; Juliana Gazallo; Ali Motabar; Padmini Varadrajan; Prakash C Deedwania; Ramdas G Pai
Journal:  Int J Angiol       Date:  2015-06

5.  Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients.

Authors:  Hamid Moradi; Elani Streja; Moti L Kashyap; Nosratola D Vaziri; Gregg C Fonarow; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2014-02-25       Impact factor: 5.992

6.  Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

Authors:  Madeleine V Pahl; Zhenmin Ni; Lili Sepassi; Hamid Moradi; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

Review 7.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

8.  High-calorie diet partially ameliorates dysregulation of intrarenal lipid metabolism in remnant kidney.

Authors:  Hyun Ju Kim; Jun Yuan; Keith Norris; Nosratola D Vaziri
Journal:  J Nutr Biochem       Date:  2009-12-01       Impact factor: 6.048

Review 9.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

10.  Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.

Authors:  Hyun Ju Kim; Hamid Moradi; Jun Yuan; Keith Norris; Nosratola D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.